CN111214464A - 包含15-hepe的组合物以及其使用方法 - Google Patents

包含15-hepe的组合物以及其使用方法 Download PDF

Info

Publication number
CN111214464A
CN111214464A CN201911258822.9A CN201911258822A CN111214464A CN 111214464 A CN111214464 A CN 111214464A CN 201911258822 A CN201911258822 A CN 201911258822A CN 111214464 A CN111214464 A CN 111214464A
Authority
CN
China
Prior art keywords
ohepa
fatty liver
disease
present
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911258822.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·罗维
K·达菲
J·克莱麦克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DS Biopharma Ltd
Original Assignee
DS Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DS Biopharma Ltd filed Critical DS Biopharma Ltd
Publication of CN111214464A publication Critical patent/CN111214464A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
CN201911258822.9A 2013-01-30 2014-01-24 包含15-hepe的组合物以及其使用方法 Pending CN111214464A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1301626.6 2013-01-30
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
CN201480006443.XA CN105120872B (zh) 2013-01-30 2014-01-24 包含15-hepe的组合物以及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480006443.XA Division CN105120872B (zh) 2013-01-30 2014-01-24 包含15-hepe的组合物以及其使用方法

Publications (1)

Publication Number Publication Date
CN111214464A true CN111214464A (zh) 2020-06-02

Family

ID=47891001

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911258822.9A Pending CN111214464A (zh) 2013-01-30 2014-01-24 包含15-hepe的组合物以及其使用方法
CN201480006443.XA Active CN105120872B (zh) 2013-01-30 2014-01-24 包含15-hepe的组合物以及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480006443.XA Active CN105120872B (zh) 2013-01-30 2014-01-24 包含15-hepe的组合物以及其使用方法

Country Status (27)

Country Link
US (6) US20150224076A1 (https=)
EP (2) EP2762143B1 (https=)
JP (2) JP6363104B2 (https=)
KR (6) KR20230047201A (https=)
CN (2) CN111214464A (https=)
AU (2) AU2014211628B2 (https=)
BR (1) BR112015018270A2 (https=)
CA (1) CA2897343C (https=)
CY (1) CY1117209T1 (https=)
DK (1) DK2762143T3 (https=)
ES (2) ES2564025T3 (https=)
GB (1) GB201301626D0 (https=)
HR (1) HRP20160203T1 (https=)
HU (1) HUE026901T2 (https=)
IL (3) IL239893A (https=)
MX (2) MX364646B (https=)
NZ (1) NZ709803A (https=)
PH (1) PH12015501582B1 (https=)
PL (1) PL2762143T3 (https=)
PT (1) PT2762143E (https=)
RS (1) RS54584B1 (https=)
RU (2) RU2018136872A (https=)
SG (2) SG11201505457PA (https=)
SI (1) SI2762143T1 (https=)
SM (1) SMT201600069B (https=)
WO (1) WO2014118097A1 (https=)
ZA (2) ZA201505018B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
EP3091959A4 (en) * 2014-01-10 2017-09-20 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
ES2980790T3 (es) 2015-04-28 2024-10-03 Basf As Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica
MA47141A (fr) * 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) * 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
CN1300212A (zh) * 1998-05-08 2001-06-20 西尔医疗有限公司 新颖的治疗肥胖症、高血压和脂肪肝的脂肪类似物
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
CN1410073A (zh) * 2001-09-30 2003-04-16 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
US20070265340A1 (en) * 2006-01-05 2007-11-15 Shalwitz Robert A Treatment of fatty liver
CN101652134A (zh) * 2007-03-30 2010-02-17 兴和株式会社 用于预防和/或治疗脂肪肝或非酒精性脂肪性肝炎的药物
JP2010248213A (ja) * 2000-02-16 2010-11-04 Brigham & Womens Hospital Inc アスピリン誘発脂質メディエータ
TW201039829A (en) * 2009-02-20 2010-11-16 Univ Tokyo Novel anti-inflammatory compounds
WO2012023254A1 (ja) * 2010-08-19 2012-02-23 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
WO2014019919A1 (en) * 2012-07-30 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-ohepa and methods of using the same
CN104684389A (zh) * 2012-05-10 2015-06-03 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール．ピー．シェーラー コーポレイション 香料を小分けして提供する方法および組成物
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
ATE291910T1 (de) 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
EP3285072B1 (en) 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20110105510A1 (en) * 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
WO2012031125A2 (en) 2010-09-01 2012-03-08 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
RU2014119948A (ru) 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2015500639A (ja) 2011-11-29 2015-01-08 ディグニティ サイエンシス リミテッド ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
CN1300212A (zh) * 1998-05-08 2001-06-20 西尔医疗有限公司 新颖的治疗肥胖症、高血压和脂肪肝的脂肪类似物
JP2010248213A (ja) * 2000-02-16 2010-11-04 Brigham & Womens Hospital Inc アスピリン誘発脂質メディエータ
CN1410073A (zh) * 2001-09-30 2003-04-16 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
US20070265340A1 (en) * 2006-01-05 2007-11-15 Shalwitz Robert A Treatment of fatty liver
CN101652134A (zh) * 2007-03-30 2010-02-17 兴和株式会社 用于预防和/或治疗脂肪肝或非酒精性脂肪性肝炎的药物
TW201039829A (en) * 2009-02-20 2010-11-16 Univ Tokyo Novel anti-inflammatory compounds
WO2012023254A1 (ja) * 2010-08-19 2012-02-23 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
CN104684389A (zh) * 2012-05-10 2015-06-03 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
WO2014019919A1 (en) * 2012-07-30 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-ohepa and methods of using the same

Also Published As

Publication number Publication date
HUE026901T2 (en) 2016-07-28
BR112015018270A2 (pt) 2017-07-18
ZA201505018B (en) 2017-01-25
KR20150112995A (ko) 2015-10-07
JP6363104B2 (ja) 2018-07-25
CN105120872A (zh) 2015-12-02
KR20250105691A (ko) 2025-07-08
HRP20160203T1 (hr) 2016-03-25
SI2762143T1 (sl) 2016-04-29
PL2762143T3 (pl) 2016-06-30
JP2018172409A (ja) 2018-11-08
US20250186384A1 (en) 2025-06-12
EP2762143A1 (en) 2014-08-06
CA2897343C (en) 2021-03-16
IL239893A (en) 2017-04-30
MX364646B (es) 2019-05-03
AU2018206685A1 (en) 2018-08-02
RU2015136849A (ru) 2017-03-06
DK2762143T3 (en) 2016-03-07
KR102434817B1 (ko) 2022-08-19
IL265876A (en) 2019-06-30
PT2762143E (pt) 2016-03-28
SMT201600069B (it) 2016-04-29
IL239893A0 (en) 2015-08-31
MX2019005082A (es) 2019-08-12
US20150224076A1 (en) 2015-08-13
SG11201505457PA (en) 2015-08-28
KR102514913B1 (ko) 2023-03-27
CY1117209T1 (el) 2017-04-05
JP2016511753A (ja) 2016-04-21
IL251639A0 (en) 2017-06-29
GB201301626D0 (en) 2013-03-13
EP3058943B1 (en) 2019-09-25
US20220347147A1 (en) 2022-11-03
MX2015009803A (es) 2015-10-29
KR20230047201A (ko) 2023-04-06
NZ709803A (en) 2020-05-29
CN105120872B (zh) 2020-01-10
ES2759448T3 (es) 2020-05-11
AU2014211628B2 (en) 2018-04-19
PH12015501582A1 (en) 2015-10-05
HK1200351A1 (en) 2015-08-07
RS54584B1 (sr) 2016-08-31
EP2762143B1 (en) 2015-12-02
KR20210088733A (ko) 2021-07-14
AU2014211628A1 (en) 2015-07-30
WO2014118097A1 (en) 2014-08-07
PH12015501582B1 (en) 2019-10-25
RU2018136872A (ru) 2018-11-27
SG10201806854XA (en) 2018-09-27
KR20220119524A (ko) 2022-08-29
ES2564025T3 (es) 2016-03-17
EP3058943A1 (en) 2016-08-24
RU2671208C2 (ru) 2018-10-30
US20210244697A1 (en) 2021-08-12
ZA201605125B (en) 2018-06-27
KR20240011872A (ko) 2024-01-26
US20210228524A1 (en) 2021-07-29
US20200069626A1 (en) 2020-03-05
KR102274963B1 (ko) 2021-07-08
US10813903B2 (en) 2020-10-27
CA2897343A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
US20250186384A1 (en) Compositions comprising 15-ohepa and methods of using the same
KR20200055154A (ko) 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
CN112245419A (zh) 包括15-hepe的组合物以及使用其治疗或预防纤维化的方法
CN113893240A (zh) 包含15-hepe的组合物和其使用方法
CN113896628A (zh) 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
HK1200351B (en) Compositions comprising 15-hepe and methods of using the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Ai Erlandubailin

Applicant after: Efimoen GmbH

Address before: Ai Erlandubailin

Applicant before: AF Immunology Co.,Ltd.

CB02 Change of applicant information